VIPR1 and schizophrenia: The VPAC receptors, in particular VPAC1, are very promising targets for the development of therapeutic molecules in various pathologies including asthma, chronic inflammation diseases (Crohn's disease, rhumatoid arthritis, septic shock, multiple sclerosis...) neurodegenerative disorders, schizophrenia.